BJE6-106
Based on 6 publication(s) in Google Scholar
BJE6-106 (B106) is a potent, selective 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis. BJE6-106 (B106) possesses tumor-specific effect.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.85%
- CAS. Nr.: 1564249-38-2
- Formel: C26H23NO2
- Molecular Weight:381.47
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
TGF-beta/Smad Compound Library
HY-L018
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Cytoskeleton Compound Library
HY-L060
-
Targeted Diversity Library
HY-L099
-
Cancer Stem Cells Compound Library
HY-L135
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) BJE6-106
More
Biologische Aktivität
|
PKCδ 0.05 μM (IC50) |
PKCα 50 μM (IC50) |
BJE6-106 (B106) (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations[1]. BJE6-106 (B106) (0.2 μM, 0.5 μM; 6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells[1]. BJE6-106 (B106) (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing MKK4, JNK and H2AX activation at different times in SBcl2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Melanoma cell lines with NRAS mutations: SBcl2, FM6, SKMEL2, WM1366, WM1361A, and WM852 cells
-
Concentration:0.2 μM, 0.5 μM
-
Incubation Time:24 hours, 48 hours, or 72 hours
-
Result:Inhibited cell survival in melanoma cell lines.
-
Cell Line:SBcl2 cells
-
Concentration:0.2 μM, 0.5 μM
-
Incubation Time:6 hours, 12 hours, or 24 hours
-
Result:Induced caspase 3/7 activation.
-
Cell Line:SBcl2 cells
-
Concentration:0.2 μM, 0.5 μM
-
Incubation Time:2 hours, 5 hours, 10 hours
-
Result:Increased phosphorylation of MKK4, JNK and H2AX.
Chemical Information
-
CAS. Nr. 1564249-38-2
-
Appearance Solid
-
Molecular Weight 381.47
-
Formel C26H23NO2
-
Color White to off-white
-
SMILES
O=CC1=C2C(C=CC(C)(C)O2)=CC(CCN3C4=C(C5=C3C=CC=C5)C=CC=C4)=C1
-
Synonyms
B106
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Differ
SUMOylation-stabilized G6PD orchestrates metabolic rewiring for oxidative stress survival and chemoresistance in HCC via a PKCδ-phosphorylation trigger. [Abstract]2026 Jun 26. PMID: 42362742 -
Int Immunopharmacol
Osthole alleviates neuropathic pain by suppressing astrocytes activation and associated inflammatory responses via the PKCδ/TRPV4 signaling pathway. [Abstract]2025 Sep 10:165:115453. PMID: 40934539 -
Mol Pharmacol
Bryostatins 1 and 3 inhibit TRPM8 and modify TRPM8- and TRPV1-mediated lung epithelial cell responses to a proinflammatory stimulus via protein kinase C. [Abstract]2025 Jun;107(6):100042. PMID: 40378651 -
-
-
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (131.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.55 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6214 mL | 13.1072 mL | 26.2144 mL | 65.5360 mL |
| 5 mM | 0.5243 mL | 2.6214 mL | 5.2429 mL | 13.1072 mL | |
| 10 mM | 0.2621 mL | 1.3107 mL | 2.6214 mL | 6.5536 mL | |
| 15 mM | 0.1748 mL | 0.8738 mL | 1.7476 mL | 4.3691 mL | |
| 20 mM | 0.1311 mL | 0.6554 mL | 1.3107 mL | 3.2768 mL | |
| 25 mM | 0.1049 mL | 0.5243 mL | 1.0486 mL | 2.6214 mL | |
| 30 mM | 0.0874 mL | 0.4369 mL | 0.8738 mL | 2.1845 mL | |
| 40 mM | 0.0655 mL | 0.3277 mL | 0.6554 mL | 1.6384 mL | |
| 50 mM | 0.0524 mL | 0.2621 mL | 0.5243 mL | 1.3107 mL | |
| 60 mM | 0.0437 mL | 0.2185 mL | 0.4369 mL | 1.0923 mL | |
| 80 mM | 0.0328 mL | 0.1638 mL | 0.3277 mL | 0.8192 mL | |
| 100 mM | 0.0262 mL | 0.1311 mL | 0.2621 mL | 0.6554 mL |
BJE6-106 Related Classifications
HY-117800 Related Classifications
Powered by Bioz